A citation-based method for searching scientific literature


List of co-cited articles
17 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Severe hypoglycemia and risks of vascular events and death.
Sophia Zoungas, Anushka Patel, John Chalmers, Bastiaan E de Galan, Qiang Li, Laurent Billot, Mark Woodward, Toshiharu Ninomiya, Bruce Neal, Stephen MacMahon,[...]. N Engl J Med 2010
920
75

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.
Bo Ahrén, Anja Schweizer, Sylvie Dejager, Beth E Dunning, Peter M Nilsson, Margaretha Persson, James E Foley. J Clin Endocrinol Metab 2009
136
75

Mean amplitude of glycemic excursions, a measure of diabetic instability.
F J Service, G D Molnar, J W Rosevear, E Ackerman, L C Gatewood, W F Taylor. Diabetes 1970
826
50

Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans.
Mikkel Christensen, Louise Vedtofte, Jens J Holst, Tina Vilsbøll, Filip K Knop. Diabetes 2011
173
50

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.
Denise E Bonds, Michael E Miller, Richard M Bergenstal, John B Buse, Robert P Byington, Jeff A Cutler, R James Dudl, Faramarz Ismail-Beigi, Angela R Kimel, Byron Hoogwerf,[...]. BMJ 2010
612
50

Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
50

Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open-label, active-controlled, 12-week study (STABLE II study).
Soo Heon Kwak, You-Cheol Hwang, Jong Chul Won, Ji Cheol Bae, Hyun Jin Kim, Sunghwan Suh, Eun Young Lee, Subin Lee, Sang-Yong Kim, Jae Hyeon Kim. Diabetes Obes Metab 2020
6
50

Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
Ayako Fuchigami, Fumika Shigiyama, Toru Kitazawa, Yosuke Okada, Takamasa Ichijo, Mariko Higa, Toru Hiyoshi, Ikuo Inoue, Kaoru Iso, Hidenori Yoshii,[...]. Cardiovasc Diabetol 2020
23
50

Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study).
Kyu Yong Cho, Hiroshi Nomoto, Akinobu Nakamura, Shinichiro Kawata, Hajime Sugawara, Jun Takeuchi, So Nagai, Kazuhisa Tsuchida, Kazuno Omori, Hiroki Yokoyama,[...]. Diabetes Obes Metab 2020
7
50

Effect of short-term treatment with sitagliptin or glibenclamide on daily glucose fluctuation in drug-naïve Japanese patients with type 2 diabetes mellitus.
Ryo Suzuki, Jun-Ichi Eiki, Takashi Moritoyo, Kenichi Furihata, Akira Wakana, Yukari Ohta, Shigeru Tokita, Takashi Kadowaki. Diabetes Obes Metab 2018
4
50

Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.
Seiichi Tanaka, Kunihiro Suzuki, Chie Aoki, Mai Niitani, Kanako Kato, Takanori Tomotsune, Yoshimasa Aso. Diabetes Technol Ther 2014
17
50

The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus.
Gyuri Kim, Sewon Oh, Sang-Man Jin, Kyu Yeon Hur, Jae Hyeon Kim, Moon-Kyu Lee. Expert Opin Pharmacother 2017
15
50

Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Bo Ahrén, James E Foley, Ele Ferrannini, David R Matthews, Bernard Zinman, Sylvie Dejager, Vivian A Fonseca. Diabetes Care 2010
67
50

Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy.
Yutaka Mori, Yukiko Taniguchi, Shigeru Miyazaki, Junichi Yokoyama, Kazunori Utsunomiya. Diabetes Technol Ther 2013
19
50

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes.
V Fonseca, A Schweizer, D Albrecht, M A Baron, I Chang, S Dejager. Diabetologia 2007
289
50

Effects of Vildagliptin Add-on Insulin Therapy on Nocturnal Glycemic Variations in Uncontrolled Type 2 Diabetes.
Feng-Fei Li, Yun Shen, Rui Sun, Dan-Feng Zhang, Xing Jin, Xiao-Fang Zhai, Mao-Yuan Chen, Xiao-Fei Su, Jin-Dan Wu, Lei Ye,[...]. Diabetes Ther 2017
7
50

Efficacy of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion (CSII) in Hospitalized Patients with Type 2 Diabetes.
Fu-Ping Lyu, Bing-Kun Huang, Wei-Juan Su, Fang-Fang Yan, Jin-Yang Zeng, Zheng Chen, Yu-Xian Zhang, Shun-Hua Wang, Yin-Xiang Huang, Mu-Lin Zhang,[...]. Diabetes Ther 2020
2
100


Update on insulin therapy for type 2 diabetes.
Thomas Donner, Miguel Muñoz. J Clin Endocrinol Metab 2012
22
25

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
25

Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy.
Seiya Shimoda, Shinsuke Iwashita, Shinji Ichimori, Yasuto Matsuo, Rieko Goto, Takako Maeda, Tomoko Matsuo, Taiji Sekigami, Junji Kawashima, Tatsuya Kondo,[...]. Endocr J 2013
19
25

Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition.
S P Rajeev, D J Cuthbertson, J P H Wilding. Diabetes Obes Metab 2016
46
25





The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action.
Kristine J Hare, Tina Vilsbøll, Meena Asmar, Carolyn F Deacon, Filip K Knop, Jens J Holst. Diabetes 2010
168
25

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
Caroline Bonner, Julie Kerr-Conte, Valéry Gmyr, Gurvan Queniat, Ericka Moerman, Julien Thévenet, Cédric Beaucamps, Nathalie Delalleau, Iuliana Popescu, Willy J Malaisse,[...]. Nat Med 2015
380
25

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
Aurora Merovci, Carolina Solis-Herrera, Giuseppe Daniele, Roy Eldor, Teresa Vanessa Fiorentino, Devjit Tripathy, Juan Xiong, Zandra Perez, Luke Norton, Muhammad A Abdul-Ghani,[...]. J Clin Invest 2014
467
25

Autonomic cardiac regulation during spontaneous nocturnal hypoglycemia in patients with type 1 diabetes.
Minna L Koivikko, Mikko P Tulppo, Antti M Kiviniemi, Mika A Kallio, Juha S Perkiömäki, Pasi I Salmela, K E Juhani Airaksinen, Heikki V Huikuri. Diabetes Care 2012
24
25

Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study.
J H Fuller, M J Shipley, G Rose, R J Jarrett, H Keen. Br Med J (Clin Res Ed) 1983
611
25

Glucagon-like peptide-I analogs: effects on insulin secretion and adenosine 3',5'-monophosphate formation.
D Gefel, G K Hendrick, S Mojsov, J Habener, G C Weir. Endocrinology 1990
100
25

Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control.
T Yamanouchi, Y Akanuma. Diabetes Res Clin Pract 1994
88
25

Comparison of three α-glucosidase inhibitors for glycemic control and bodyweight reduction in Japanese patients with obese type 2 diabetes.
Hitoshi Sugihara, Mototsugu Nagao, Taro Harada, Yasushi Nakajima, Kyoko Tanimura-Inagaki, Fumitaka Okajima, Hideki Tamura, Takeshi Inazawa, Takatoshi Otonari, Masanobu Kawakami,[...]. J Diabetes Investig 2014
23
25


Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel, Stephen MacMahon, John Chalmers, Bruce Neal, Laurent Billot, Mark Woodward, Michel Marre, Mark Cooper, Paul Glasziou, Diederick Grobbee,[...]. N Engl J Med 2008
25


Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
I M Stratton, A I Adler, H A Neil, D R Matthews, S E Manley, C A Cull, D Hadden, R C Turner, R R Holman. BMJ 2000
25

Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics.
A M Abbatecola, M R Rizzo, M Barbieri, R Grella, A Arciello, M T Laieta, R Acampora, N Passariello, F Cacciapuoti, G Paolisso. Neurology 2006
98
25




Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide.
Kyoko Kudo-Fujimaki, Takahisa Hirose, Tomoaki Yoshihara, Fumihiko Sato, Yuki Someya, Chie Ohmura, Akio Kanazawa, Yoshio Fujitani, Hirotaka Watada. J Diabetes Investig 2014
9
25

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
Jean-Louis Chiasson, Robert G Josse, Ramon Gomis, Markolf Hanefeld, Avraham Karasik, Markku Laakso. JAMA 2003
25

Diabetes and cardiovascular disease in a prospective population survey in Japan: The Hisayama Study.
M Fujishima, Y Kiyohara, I Kato, T Ohmura, H Iwamoto, K Nakayama, S Ohmori, T Yoshitake. Diabetes 1996
188
25

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.
Pablo Aschner, Mark S Kipnes, Jared K Lunceford, Matilde Sanchez, Carolyn Mickel, Debora E Williams-Herman. Diabetes Care 2006
632
25

Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes.
Daisuke Yabe, Koin Watanabe, Kenji Sugawara, Hitoshi Kuwata, Yuka Kitamoto, Kazu Sugizaki, Shuichi Fujiwara, Masahiro Hishizawa, Takanori Hyo, Kyoko Kuwabara,[...]. J Diabetes Investig 2012
54
25

Glucose control and vascular complications in veterans with type 2 diabetes.
William Duckworth, Carlos Abraira, Thomas Moritz, Domenic Reda, Nicholas Emanuele, Peter D Reaven, Franklin J Zieve, Jennifer Marks, Stephen N Davis, Rodney Hayward,[...]. N Engl J Med 2009
25

Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
Tomoya Mita, Naoto Katakami, Hidenori Yoshii, Tomio Onuma, Hideaki Kaneto, Takeshi Osonoi, Toshihiko Shiraiwa, Keisuke Kosugi, Yutaka Umayahara, Tsunehiko Yamamoto,[...]. Diabetes Care 2016
99
25



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.